How to draw up tirzepatide — and why the question itself matters

Why the phrase 'drawing up' signals a different product altogether

The Mounjaro KwikPen is designed so that no preparation is required before injecting. You attach a new needle, dial nothing (the dose is fixed per pen), and inject into the abdomen, thigh or upper arm. That simplicity is deliberate: it removes the scope for dosing errors that a vial-and-syringe system introduces.

The instruction to 'draw up' tirzepatide appears in the context of compounded or raw tirzepatide, where the peptide is supplied as a powder or liquid in a vial and the user reconstitutes it, measures a volume in a syringe and self-injects that measured amount. This is a fundamentally different process, and not one covered by the licensed medicine's Patient Information Leaflet. If you have arrived at this page after seeing those instructions elsewhere, our page on raw tirzepatide explains what that category of product actually is and why UK regulators treat it very differently from the licensed KwikPen.

There is also a separate category worth knowing about: instructions for mixing tirzepatide follow a similar vial-based process and carry the same concerns. The MHRA has been unambiguous that tirzepatide, which our dedicated page covers in full, supplied for injection should be obtained through a licensed pharmacy on a valid prescription, and the agency has specifically warned about unlicensed peptide preparations circulating online.

What using the licensed KwikPen actually involves

For people who are prescribed Mounjaro through a legitimate route, the injection process is straightforward. Each pen contains four weekly doses at a fixed strength. Before your first injection your prescriber or pharmacist will walk you through the steps, and the full procedure is set out in the Patient Information Leaflet, the authoritative reference for your specific pen and strength. The NHS tirzepatide page also carries a clear summary.

In brief, the licensed process involves washing your hands, attaching a new sterile needle, checking the liquid in the window is clear and colourless, choosing an injection site (rotating it each week), inserting the needle, pressing the button until you hear a click and then holding for a further ten seconds to ensure the full dose is delivered. You dispose of the used needle immediately in an approved sharps container.

Storage matters too: the pen lives in the fridge at 2–8°C, many people keep it in the fridge door, separate from food. If you need to carry it with you, the SmPC specifies a room-temperature window; check the leaflet for the exact timeframe rather than relying on any third-party source, since those details are strength-specific. Questions about missed doses, early dose increases or switching between preparations should go to your prescriber or the Patient Information Leaflet, not a forum.

People prescribed Mounjaro through treatment at nume receive the pen from a GPhC-registered pharmacy using the licensed UK supply chain, which is why the product they receive behaves exactly as the SmPC describes.

The safety case for the licensed route over vial-based preparations

This is the section most worth reading carefully. When tirzepatide is supplied as a vial for drawing up, several things change: concentration must be calculated, volume must be measured accurately, sterility must be maintained during reconstitution, and the source of the peptide itself must be trusted. Any error at any of those steps carries a real clinical risk.

The MHRA's enforcement work has found fake and substandard weight-loss preparations sold online, some containing entirely wrong substances. Buying from an unverified seller (one offering injectable products without a prescription and a proper clinical assessment) removes every safeguard the licensing system exists to provide. You can check whether any online pharmacy is legitimate using the GPhC pharmacy register, which is searchable by name or registration number.

For people who are currently on a compounded preparation and want to understand what switching to the licensed medicine looks like, the process of stopping or transitioning off tirzepatide is something a prescriber can advise on individually. The decision to switch (and at what dose to restart) is a clinical one, not a self-managed step.

If you are considering tirzepatide for the first time and are wondering about the cost of private treatment, our weight-loss treatment overview explains how pricing works for licensed medicines and what a legitimate private prescription includes.

What a genuine prescribing consultation looks at before approving treatment

Because tirzepatide is a prescription-only medicine, no version of it (licensed pen or otherwise) should be in your hands without a prescriber having reviewed your health history. A proper assessment looks at BMI, any weight-related conditions, current medicines (particularly oral contraceptives, where tirzepatide can reduce absorption during the first four weeks of treatment and after each dose increase), and any contraindications including a personal or family history of certain thyroid conditions.

At nume, that assessment is done by a GPhC-registered Independent Prescriber (a real clinician reads your answers the same day) and is repeated before every repeat order. There is no auto-renewal. Identity and current weight are verified, and the prescriber reviews your progress before authorising the next pen. Our clinical team page sets out who is responsible for those decisions.

The question of how to draw up tirzepatide is, ultimately, best resolved by ensuring you are using a form of tirzepatide that does not need drawing up, and our page on how to make tirzepatide walks through exactly why that preparation process exists and what it entails. If you have questions about starting treatment or about anything in this page, our FAQs cover the most common ones, and the team is available seven days a week.